Get a deeper insight into the potential performance of Steris (STE) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
STERIS' (STE) first-quarter fiscal 2025 results are likely to reflect the positives of the normalization of the Healthcare backlog, along with a core focus on pharma and MedTech.
STERIS' (STE) AST successfully offers an extensive range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.
STERIS' (STE) Healthcare business and strong rebound prospects of the AST segment appear encouraging. However, macroeconomic concerns remain a challenge.
STERIS' (STE) AST successfully offers a wide range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.
Steris (STE) reported earnings 30 days ago. What's next for the stock?